Aspicio Therapeutics, Inc.
New Form D on file · 2026-07-17 · the record
What the record says
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 810 filings in Other Health Care, totalled by week. The dot is this raise, $200K, on the same scale — one filing against the whole group's total, so it sits low by construction.
Company officers on record
Michael Keane is named as Executive Officer and Director on the Form D that Aspicio Therapeutics, Inc. filed with the SEC on 17 July 2026, the only person that filing names.
1 person named on the filing — 1 holding an executive role.
Named as of the 2026-07-17 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
The full profile
Source Check, INVEST, RECRUIT and Press Requests on Aspicio Therapeutics, Inc.
- Source Check — verify Michael Keane's other claims against the registers that hold them.
- INVEST — size up this raise on the figures the filing states.
- RECRUIT — see who is already on the team.
- Press Requests — connect with Michael Keane for a story.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Aspicio Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind Aspicio Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. FoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.